180 related articles for article (PubMed ID: 34322652)
1. Comprehensive Breast Cancer Risk Assessment for
Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
[TBL] [Abstract][Full Text] [Related]
2. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
[TBL] [Abstract][Full Text] [Related]
4. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
6. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
[TBL] [Abstract][Full Text] [Related]
7. Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.
Hughes E; Tshiaba P; Wagner S; Judkins T; Rosenthal E; Roa B; Gallagher S; Meek S; Dalton K; Hedegard W; Adami CA; Grear DF; Domchek SM; Garber J; Lancaster JM; Weitzel JN; Kurian AW; Lanchbury JS; Gutin A; Robson ME
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036224
[TBL] [Abstract][Full Text] [Related]
8. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
9. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
[TBL] [Abstract][Full Text] [Related]
10. Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
Gao C; Polley EC; Hart SN; Huang H; Hu C; Gnanaolivu R; Lilyquist J; Boddicker NJ; Na J; Ambrosone CB; Auer PL; Bernstein L; Burnside ES; Eliassen AH; Gaudet MM; Haiman C; Hunter DJ; Jacobs EJ; John EM; Lindström S; Ma H; Neuhausen SL; Newcomb PA; O'Brien KM; Olson JE; Ong IM; Patel AV; Palmer JR; Sandler DP; Tamimi R; Taylor JA; Teras LR; Trentham-Dietz A; Vachon CM; Weinberg CR; Yao S; Weitzel JN; Goldgar DE; Domchek SM; Nathanson KL; Couch FJ; Kraft P
J Clin Oncol; 2021 Aug; 39(23):2564-2573. PubMed ID: 34101481
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
[TBL] [Abstract][Full Text] [Related]
13. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
[TBL] [Abstract][Full Text] [Related]
14. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
16. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF
J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948
[TBL] [Abstract][Full Text] [Related]
17. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Lee A; Mavaddat N; Wilcox AN; Cunningham AP; Carver T; Hartley S; Babb de Villiers C; Izquierdo A; Simard J; Schmidt MK; Walter FM; Chatterjee N; Garcia-Closas M; Tischkowitz M; Pharoah P; Easton DF; Antoniou AC
Genet Med; 2019 Aug; 21(8):1708-1718. PubMed ID: 30643217
[TBL] [Abstract][Full Text] [Related]
18. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.
West AH; Blazer KR; Stoll J; Jones M; Weipert CM; Nielsen SM; Kupfer SS; Weitzel JN; Olopade OI
Fam Cancer; 2018 Oct; 17(4):495-505. PubMed ID: 29445900
[TBL] [Abstract][Full Text] [Related]
19. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
